BrainStorm Cell Therapeutics Inc (BCLI)

[midastouch017]

BrainStorm Announces Presentation of NurOwn® Exosome Preclinical Data at ISCT 2022 San Francisco Meeting

https://finance.yahoo.com/news/brainstorm-announces-presentation-nurown-exosome-100000882.html

NurOwn-derived exosomes showed more potent anti-inflammatory effects in vitro compared to naïve mesenchymal stem cell-derived exosomes

NEW YORK, May 4, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced the presentation today of a poster titled, "MSC-NTF derived small extracellular vesicles display superior macrophage immunomodulation compared with vesicles derived from naïve MSCs," at the International Society of Cell & Gene Therapy ISCT 2022 Meeting, being held from May 4-7, 2022 in San Francisco, CA. The poster will be presented by Dr. Kim Thacker, Senior Vice President, Medical Affairs and Clinical Innovation, BrainStorm Cell Therapeutics.

POSTER DETAILS:

Poster 313: MSC-NTF derived small extracellular vesicles display superior macrophage immunomodulation compared with vesicles derived from naïve MSCs.
Exosome/EV session: Wednesday May 4, 6:30 p.m. - 8:00 p.m. (Pacific Time)

POSTER HIGHLIGHTS:

Background:

NurOwn-derived exosomes (Exo MSC-NTF) are small extracellular vesicles produced from bone-marrow derived mesenchymal stem cells (MSC) induced to secrete high levels of neurotrophic and other protective factors (MSC-NTF).

Previously reported preclinical data demonstrated the superior efficacy of Exo MSC-NTF compared to exosomes produced from naïve MSCs (Exo MSC) when evaluated as a treatment for acute lung injury in mouse models.

Study Rationale and Objective:

To better understand the mechanisms underlying the superior preclinical efficacy of Exo MSC-NTF versus Exo-MSC against acute lung injury, the effects of each on macrophage secretion of inflammatory factors were assessed. Assessments were performed in vitro with both M1 (pro-inflammatory) and M2 (anti-inflammatory) polarized macrophages.

Results:

Exo MSC-NTF inhibited the expression and secretion of pro-inflammatory cytokines by M1 macrophages more potently than Exo MSC

Exo MSC-NTF upregulated the expression and secretion of anti-inflammatory cytokines by M2 macrophages

Conclusion:

Exo MSC-NTF showed more potent anti-inflammatory effects in vitro compared to Exo-MSC.

"These compelling preclinical data provide important insights into Exo MSC-NTF's mechanism of action," said Ralph Kern, MD MHSc, President and Chief Medical Officer of BrainStorm. "They suggest that the preclinical efficacy previously observed in acute lung injury models is due to the anti-inflammatory effects of Exo MSC-NTF on macrophage populations. Our scientific team is privileged to share this important finding at the International Society for Cell and Gene Therapy (ISCT), a globally recognized organization focused on translational aspects of developing cell-based therapeutics. We look forward to productive scientific engagements with experts at the meeting."

Chaim Lebovits, Chief Executive Officer of BrainStorm, added, "At BrainStorm, we are committed to exploring the full potential of our proprietary cell technology platform and continue to make key scientific progress that will enable us to address serious unmet medical needs. At the same time, we remain fully committed to advancing our cellular therapeutic pipeline in ALS and progressive MS."